[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 15 of about 15
1. Swain SM, Jeong JH, Geyer CE Jr, Costantino JP, Pajon ER, Fehrenbacher L, Atkins JN, Polikoff J, Vogel VG, Erban JK, Rastogi P, Livingston RB, Perez EA, Mamounas EP, Land SR, Ganz PA, Wolmark N: Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med; 2010 Jun 03;362(22):2053-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.
  • BACKGROUND: Chemotherapy regimens that combine anthracyclines and taxanes result in improved disease-free and overall survival among women with operable lymph-node-positive breast cancer.
  • METHODS: We randomly assigned 5351 patients with operable, node-positive, early-stage breast cancer to receive four cycles of doxorubicin and cyclophosphamide followed by four cycles of docetaxel (sequential ACT); four cycles of doxorubicin and docetaxel (doxorubicin-docetaxel); or four cycles of doxorubicin, cyclophosphamide, and docetaxel (concurrent ACT).
  • [MeSH-major] Adenocarcinoma / drug therapy. Amenorrhea / chemically induced. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Taxoids / administration & dosage
  • [MeSH-minor] Chemotherapy, Adjuvant. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Middle Aged. Multivariate Analysis. Neoplasm Staging. Premenopause. Survival Analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Massachusetts Medical Society
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):968-75 [12637459.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):976-83 [12637460.001]
  • [Cites] Breast Cancer Res Treat. 2009 Jan;113(2):315-20 [18302020.001]
  • [Cites] J Natl Cancer Inst. 2008 Aug 20;100(16):1179-83 [18695137.001]
  • [Cites] J Natl Cancer Inst. 2003 Dec 17;95(24):1833-46 [14679153.001]
  • [Cites] Control Clin Trials. 1984 Dec;5(4):348-61 [6518769.001]
  • [Cites] J Natl Cancer Inst. 1998 Aug 19;90(16):1205-11 [9719081.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1687-717 [15894097.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):5973-82 [16087950.001]
  • [Cites] Oncologist. 2006 Feb;11(2):96-110 [16476831.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):4963-70 [17033039.001]
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5769-79 [17130515.001]
  • [Cites] Lancet. 2007 May 19;369(9574):1711-23 [17512856.001]
  • [CommentIn] N Engl J Med. 2010 Jun 3;362(22):2122-4 [20519684.001]
  • [CommentIn] N Engl J Med. 2010 Dec 2;363(23):2268-70 [21121855.001]
  • [CommentIn] Curr Treat Options Oncol. 2010 Dec;11(3-4):59-62 [21061193.001]
  • (PMID = 20519679.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00003782
  • [Grant] United States / NCI NIH HHS / CA / U10-CA-69651; United States / NCI NIH HHS / CA / U10 CA025224-25; United States / NCI NIH HHS / CA / CA07190; United States / NCI NIH HHS / CA / U10 CA069974-10; United States / NCI NIH HHS / CA / U10-CA-37377; United States / NCI NIH HHS / CA / U10 CA045808-22; United States / NCI NIH HHS / CA / N01 CA032102; United States / NCI NIH HHS / CA / N01 CA013612; United States / NCI NIH HHS / CA / U10 CA045808; United States / NCI NIH HHS / CA / U10 CA012027; United States / NCI NIH HHS / CA / U10 CA013612; United States / NCI NIH HHS / CA / U10 CA058348-10; United States / NCI NIH HHS / CA / CA-25224; United States / NCI NIH HHS / CA / CA-45808; United States / NCI NIH HHS / CA / U10-CA-69974; United States / NCI NIH HHS / CA / CA-58348; United States / NCI NIH HHS / CA / U10-CA-12027; United States / NCI NIH HHS / CA / CA2115; United States / NCI NIH HHS / CA / CA-13612; United States / NCI NIH HHS / CA / CA-32102; United States / NCI NIH HHS / CA / U10 CA069651; United States / NCI NIH HHS / CA / U10 CA032102; United States / NCI NIH HHS / CA / U10 CA069974; United States / NCI NIH HHS / CA / U10 CA012027-35; United States / NCI NIH HHS / CA / U10 CA007190; United States / NCI NIH HHS / CA / U10 CA069651-09; United States / NCI NIH HHS / CA / U10 CA013612-35; United States / NCI NIH HHS / CA / U10 CA025224; United States / NCI NIH HHS / CA / U10 CA032102-30; United States / NCI NIH HHS / CA / U10 CA037377-18; United States / NCI NIH HHS / CA / U10 CA037377
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  • [Other-IDs] NLM/ NIHMS212423; NLM/ PMC2935316
  •  go-up   go-down


2. Ohshima H, Yamashiro K, Yamamoto M, Hirata K, Okazaki A, Ohmura T, Okazaki M, Watanabe Y: [Clinical study of selective intra-arterial infusion chemotherapy using trans-radial arterial approach in 4 cases of advanced breast cancer]. Gan To Kagaku Ryoho; 2000 Feb;27(2):239-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical study of selective intra-arterial infusion chemotherapy using trans-radial arterial approach in 4 cases of advanced breast cancer].
  • We administered neoadjuvant chemotherapy by a selective intra-arterial infusion method using a trans-radial approach in patients with advanced breast cancer (stage III and stage IV).
  • In this method, the radial artery is cannulated, and epirubucin is infused into the artery that carries blood from the subclavical artery to the breast.
  • However, the currently available catheters are not always able to approach the artery flowing into the breast, thus the protocol will need to be refined.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Breast Neoplasms / drug therapy. Epirubicin / administration & dosage. Infusions, Intra-Arterial / methods
  • [MeSH-minor] Adenocarcinoma, Scirrhous / drug therapy. Adult. Aged. Carcinoma, Ductal, Breast / drug therapy. Drug Administration Schedule. Female. Humans. Middle Aged. Neoadjuvant Therapy. Radial Artery

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10700894.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 3Z8479ZZ5X / Epirubicin
  •  go-up   go-down


3. Rossi D, Dennetta D, Ugolini M, Alessandroni P, Catalano V, Fedeli SL, Giordani P, Casadei V, Baldelli AM, Graziano F, Catalano G: Weekly paclitaxel in elderly patients (aged > or = 70 years) with advanced non-small-cell lung cancer: an alternative choice? Results of a phase II study. Clin Lung Cancer; 2008 Sep;9(5):280-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In recent years, weekly paclitaxel has been widely used for its safety profile, especially in breast and ovarian cancer.
  • The aim of our study was to investigate the activity and safety of weekly paclitaxel in elderly patients with locally advanced (stage IIIB) and metastatic (stage IV) NSCLC.
  • PATIENTS AND METHODS: Twenty-seven patients entered the study; 10 had stage IIIB disease (5 "wet" and 5 "dry"), and 17 had stage IV disease.
  • Phase III studies that compare these third-generation drugs are warranted to draw definitive conclusion about the best approach in these patients.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Paclitaxel / therapeutic use
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Aged. Aged, 80 and over. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Carcinoma / drug therapy. Carcinoma / secondary. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Female. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Male. Prognosis. Salvage Therapy. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18824450.001).
  • [ISSN] 1525-7304
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


Advertisement
4. Health Quality Ontario: Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis. Ont Health Technol Assess Ser; 2010;10(24):1-48
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
  • For each technology, an economic analysis was also completed by the Toronto Health Economics and Technology Assessment Collaborative (THETA) and is summarized within the reports.THE FOLLOWING REPORTS CAN BE PUBLICLY ACCESSED AT THE MAS WEBSITE AT: http://www.health.gov.on.ca/mas or at www.health.gov.on.ca/english/providers/program/mas/mas_about.htmlGENE EXPRESSION PROFILING FOR GUIDING ADJUVANT CHEMOTHERAPY DECISIONS IN WOMEN WITH EARLY BREAST CANCER: An Evidence-Based AnalysisEpidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: an Evidence-Based AnalysisK-RAS testing in Treatment Decisions for Advanced Colorectal Cancer: an Evidence-Based Analysis OBJECTIVE: The Medical Advisory Secretariat undertook a systematic review of the evidence on the clinical effectiveness and cost-effectiveness of epidermal growth factor receptor (EGFR) mutation testing compared with no EGFR mutation testing to predict response to tyrosine kinase inhibitors (TKIs), gefitinib (Iressa(®)) or erlotinib (Tarceva(®)) in patients with advanced non-small cell lung cancer (NSCLC).
  • Treatment for refractory or relapsed disease includes single-agent treatment with docetaxel, pemetrexed or EGFR-targeting TKIs (gefitinib, erlotinib).
  • Certain patient characteristics (adenocarcinoma, non-smoking history, Asian ethnicity, female gender) predict for better survival benefit and response to therapy with TKIs.
  • Drugs used in this therapy, however, can be costly, up to C$ 2000 to C$ 3000 per month, and they have only approximately a 10% chance of benefiting unselected patients.
  • Other techniques have been developed for the simple, but highly sensitive detection of specific EGFR mutations, such as the amplification refractory mutations system (ARMS) and the peptide nucleic acid-locked PCR clamping.
  • Others selectively digest wild-type DNA templates with restriction endonucleases to enrich mutant alleles by PCR.
  • The inclusion criteria were as follows: POPULATION: patients with locally advanced or metastatic NSCLC (stage IIIB or IV)PROCEDURE: EGFR mutation testing before treatment with gefitinib or erlotinibLANGUAGE: publication in EnglishPublished health technology assessments, guidelines, and peer-reviewed literature (abstracts, full text, conference abstract) OUTCOMES: progression-free survival (PFS), Objective response rate (ORR), overall survival (OS), quality of life (QoL).The exclusion criteria were as follows: Studies lacking outcomes specific to those of interestStudies focused on erlotinib maintenance therapyStudies focused on gefitinib or erlotinib use in combination with cytotoxic agents or any other drugGrey literature, where relevant, was also reviewed.
  • SUMMARY OF FINDINGS: Since the last published health technology assessment by Blue Cross Blue Shield Association in 2007 there have been a number of phase III trials which provide evidence of predictive value of EGFR mutation testing in patients who were treated with gefitinib compared to chemotherapy in the first- or second-line setting.
  • The Iressa Pan Asian Study (IPASS) trial showed the superiority of gefitinib in terms of PFS in patients with EGFR mutations versus patients with wild-type EGFR (Hazard ratio [HR], 0.48, 95%CI; 0.36-0.64 versus HR, 2.85; 95%CI, 2.05-3.98).
  • Moreover, there was a statistically significant increased ORR in patients who received gefitinib and had EGFR mutations compared to patients with wild-type EGFR (71% versus 1%).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1992 Sep 1;70(5):1102-10 [1515985.001]
  • [Cites] J Clin Oncol. 1991 Aug;9(8):1453-61 [1649267.001]
  • [Cites] J Clin Oncol. 1988 Apr;6(4):633-41 [2833577.001]
  • [Cites] Methods Enzymol. 1983;99:379-87 [6196602.001]
  • [Cites] Int J Technol Assess Health Care. 1994 Fall;10(4):714-5 [7843894.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):191-202 [8000996.001]
  • [Cites] Pharmacoeconomics. 1995 Oct;8(4):316-23 [10155673.001]
  • [Cites] Lung Cancer. 1999 Apr;24(1):17-24 [10403690.001]
  • [Cites] Int J Biochem Cell Biol. 1999 Jun;31(6):637-43 [10404636.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):12-8 [10458212.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3522-30 [10550150.001]
  • [Cites] Ann Oncol. 1999;10 Suppl 5:S3-6 [10582131.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):122-30 [10623702.001]
  • [Cites] Lung Cancer. 2000 Mar;27(3):145-57 [10699688.001]
  • [Cites] J Clin Oncol. 2000 May;18(10):2095-103 [10811675.001]
  • [Cites] Br J Cancer. 2000 Aug;83(4):447-53 [10945489.001]
  • [Cites] Cancer. 2000 Oct 15;89(8):1714-9 [11042565.001]
  • [Cites] Ann Oncol. 2000 Oct;11(10):1295-300 [11106119.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):92-8 [11784875.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1344-52 [11870178.001]
  • [Cites] Semin Oncol. 2003 Feb;30(1 Suppl 1):3-11 [12644979.001]
  • [Cites] Exp Cell Res. 2003 Mar 10;284(1):31-53 [12648464.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2237-46 [12748244.001]
  • [Cites] Cancer. 2003 Jul 15;98(2):337-43 [12872354.001]
  • [Cites] Lung Cancer. 2003 Sep;41(3):321-31 [12928123.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3207-13 [12947054.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3798-807 [12953099.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1192-9 [14520444.001]
  • [Cites] JAMA. 2003 Oct 22;290(16):2149-58 [14570950.001]
  • [Cites] Ann Oncol. 2004 Jan;15(1):38-44 [14679117.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1589-97 [15117980.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Br J Cancer. 2004 Jul 19;91(2):208-12 [15187994.001]
  • [Cites] BMJ. 2004 Jun 19;328(7454):1490 [15205295.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3238-47 [15310767.001]
  • [Cites] Br J Cancer. 2004 Dec 13;91(12):1996-2004 [15558071.001]
  • [Cites] Br J Cancer. 2005 Jan 17;92(1):15-20 [15597104.001]
  • [Cites] Ann Oncol. 2005 Jan;16(1):90-6 [15598944.001]
  • [Cites] Eur J Cancer. 2005 Jan;41(1):81-92 [15617993.001]
  • [Cites] Ann Oncol. 2005 Feb;16(2):294-9 [15668287.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):857-65 [15681531.001]
  • [Cites] Ann Oncol. 2005 Apr;16(4):538-48 [15746148.001]
  • [Cites] J Natl Cancer Inst. 2005 May 4;97(9):643-55 [15870435.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6838-45 [15998906.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6829-37 [15998907.001]
  • [Cites] Chest. 2005 Jul;128(1):452-62 [16002972.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):123-32 [16014882.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):133-44 [16014883.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5007-18 [16051952.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8081-92 [16204011.001]
  • [Cites] Lancet. 2005 Oct 29-Nov 4;366(9496):1527-37 [16257339.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8389-95 [16293869.001]
  • [Cites] Jpn J Clin Oncol. 2005 Dec;35(12):700-6 [16303792.001]
  • [Cites] Ann Oncol. 2006 Mar;17(3):467-72 [16371411.001]
  • [Cites] Lung Cancer. 2006 Apr;52(1):75-81 [16488054.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1428-34 [16549837.001]
  • [Cites] Anticancer Drugs. 2006 Apr;17(4):401-9 [16549997.001]
  • [Cites] Lung Cancer. 2006 May;52(2):155-63 [16569462.001]
  • [Cites] Chest. 2006 Apr;129(4):1031-8 [16608954.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3078-84 [16707605.001]
  • [Cites] Int J Clin Oncol. 2006 Jun;11(3):190-8 [16850125.001]
  • [Cites] J Clin Oncol. 2006 Oct 1;24(28):4539-44 [17008692.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5034-42 [17075123.001]
  • [Cites] Ann Oncol. 2007 Feb;18(2):317-23 [17079694.001]
  • [Cites] Clin Cancer Res. 2006 Dec 15;12(24):7232-41 [17189394.001]
  • [Cites] Int J Cancer. 2007 Mar 15;120(6):1239-47 [17192902.001]
  • [Cites] Ann Oncol. 2007 Apr;18(4):752-60 [17317677.001]
  • [Cites] Cancer. 2007 May 1;109(9):1836-44 [17387741.001]
  • [Cites] J Thorac Oncol. 2006 Oct;1(8):837-46 [17409968.001]
  • [Cites] Lung Cancer. 2007 Aug;57(2):168-74 [17467848.001]
  • [Cites] Lung Cancer. 2007 Oct;58(1):80-7 [17588704.001]
  • [Cites] Health Qual Life Outcomes. 2008;6:6 [18208616.001]
  • [Cites] Cancer. 2008 Mar 1;112(5):1114-21 [18219661.001]
  • [Cites] J Clin Oncol. 2008 Feb 20;26(6):983-94 [18281673.001]
  • [Cites] Ann Oncol. 2008 May;19(5):939-45 [18283036.001]
  • [Cites] N Engl J Med. 2008 Mar 13;358(11):1160-74 [18337605.001]
  • [Cites] J Clin Oncol. 2008 Mar 20;26(9):1452-8 [18349395.001]
  • [Cites] J Clin Oncol. 2008 Mar 20;26(9):1472-8 [18349398.001]
  • [Cites] Lung Cancer. 2008 Dec;62(3):334-43 [18450322.001]
  • [Cites] Br J Cancer. 2008 May 20;98(10):1608-13 [18475293.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3543-51 [18506025.001]
  • [Cites] Clin Cancer Res. 2008 Jun 15;14(12):3860-6 [18559606.001]
  • [Cites] Clin Cancer Res. 2008 Jun 15;14(12):3867-74 [18559607.001]
  • [Cites] Clin Lung Cancer. 2008 May;9(3):154-9 [18621625.001]
  • [Cites] J Clin Oncol. 2008 Sep 10;26(26):4268-75 [18626007.001]
  • [Cites] Int J Med Sci. 2008;5(4):209-17 [18645621.001]
  • [Cites] Chin Med J (Engl). 2008 May 20;121(10):892-7 [18706202.001]
  • [Cites] Lancet. 2008 Nov 22;372(9652):1809-18 [19027483.001]
  • [Cites] J Thorac Oncol. 2008 Dec;3(12):1446-53 [19057271.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Jul;64(2):379-84 [19139896.001]
  • [Cites] J Clin Oncol. 2009 Mar 10;27(8):1227-34 [19188680.001]
  • [Cites] Chang Gung Med J. 2008 Nov-Dec;31(6):559-66 [19241895.001]
  • [Cites] J Clin Oncol. 2009 May 1;27(13):2253-60 [19289623.001]
  • [Cites] Eur Respir J. 2009 Jun;33(6):1485-97 [19483050.001]
  • [Cites] J Thorac Oncol. 2009 Sep;4(9):1148-55 [19546818.001]
  • [Cites] J Thorac Oncol. 2009 Aug;4(8):1002-9 [19633475.001]
  • [Cites] Oncogene. 2009 Aug;28 Suppl 1:S14-23 [19680292.001]
  • [Cites] N Engl J Med. 2009 Sep 3;361(10):947-57 [19692680.001]
  • [Cites] N Engl J Med. 2009 Sep 3;361(10):958-67 [19692684.001]
  • [Cites] Ann Oncol. 2010 Mar;21(3):556-61 [19828561.001]
  • [Cites] Lancet Oncol. 2010 Feb;11(2):121-8 [20022809.001]
  • [Cites] Clin Cancer Res. 2010 Jan 1;16(1):291-303 [20028749.001]
  • [Cites] J Clin Oncol. 2010 Feb 10;28(5):744-52 [20038723.001]
  • [Cites] Clin Cancer Res. 2010 Feb 15;16(4):1307-14 [20145166.001]
  • [Cites] J Natl Cancer Inst. 2010 Mar 3;102(5):298-306 [20160168.001]
  • [Cites] J Clin Oncol. 2010 May 1;28(13):2167-73 [20351334.001]
  • [Cites] Curr Drug Targets. 2010 Jul;11(7):851-64 [20388064.001]
  • [Cites] N Engl J Med. 2010 Jun 24;362(25):2380-8 [20573926.001]
  • [Cites] Lung Cancer. 2003 Aug;41 Suppl 1:S9-14 [12867057.001]
  • (PMID = 23074402.001).
  • [ISSN] 1915-7398
  • [Journal-full-title] Ontario health technology assessment series
  • [ISO-abbreviation] Ont Health Technol Assess Ser
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC3377519
  •  go-up   go-down


5. Marttunen MB, Cacciatore B, Hietanen P, Pyrhönen S, Tiitinen A, Wahlström T, Ylikorkala O: Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women. Br J Cancer; 2001 Apr 6;84(7):897-902
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To assess and compare the gynaecological consequences of the use of 2 antioestrogens we examined 167 postmenopausal breast cancer patients before and during the use of either tamoxifen (20 mg/day, n = 84) or toremifene (40 mg/day, n = 83) as an adjuvant treatment of stage II-III breast cancer.
  • One patient in the toremifene group developed endometrial adenocarcinoma at 12 months, and one patient had breast cancer metastasis on the endometrium.
  • [MeSH-major] Endometrium / drug effects. Estrogen Receptor Modulators / pharmacology. Postmenopause. Tamoxifen / pharmacology. Toremifene / pharmacology. Vagina / drug effects
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Agents, Hormonal / adverse effects. Antineoplastic Agents, Hormonal / pharmacology. Antineoplastic Agents, Hormonal / therapeutic use. Breast Neoplasms / drug therapy. Female. Humans. Middle Aged. Prospective Studies. Vasomotor System / drug effects

  • Hazardous Substances Data Bank. TAMOXIFEN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Cancer Research Campaign.
  • [Cites] J Natl Cancer Inst. 1994 Apr 6;86(7):527-37 [8133536.001]
  • [Cites] Am J Obstet Gynecol. 1994 Feb;170(2):447-51 [8116695.001]
  • [Cites] Cancer. 1994 Jul 1;74(1 Suppl):222-7 [8004590.001]
  • [Cites] Breast Cancer Res Treat. 1994;31(1):27-39 [7981454.001]
  • [Cites] Lancet. 1995 Jan 28;345(8944):254-5 [7823732.001]
  • [Cites] Gynecol Oncol. 1994 Dec;55(3 Pt 1):443-7 [7835785.001]
  • [Cites] J Natl Cancer Inst. 1995 May 3;87(9):645-51 [7752269.001]
  • [Cites] J Clin Oncol. 1995 Oct;13(10):2556-66 [7595707.001]
  • [Cites] Lancet. 1995 Nov 11;346(8985):1292 [7475728.001]
  • [Cites] Gynecol Oncol. 1995 Nov;59(2):261-6 [7590484.001]
  • [Cites] Am J Obstet Gynecol. 1996 Apr;174(4):1327-34 [8623865.001]
  • [Cites] Curr Opin Obstet Gynecol. 1996 Feb;8(1):27-31 [8777254.001]
  • [Cites] Br J Cancer. 1996 Jul;74(2):297-9 [8688340.001]
  • [Cites] Clin Obstet Gynecol. 1996 Sep;39(3):629-40 [8862888.001]
  • [Cites] Drugs. 1997 Jul;54(1):141-60 [9211086.001]
  • [Cites] Cancer Causes Control. 1997 Nov;8(6):821-7 [9427424.001]
  • [Cites] Oncology (Williston Park). 1998 Mar;12(3 Suppl 5):23-7 [9556787.001]
  • [Cites] Am J Obstet Gynecol. 1998 Jun;178(6):1145-50 [9662294.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88 [9747868.001]
  • [Cites] Obstet Gynecol. 1998 Oct;92(4 Pt 1):563-8 [9764629.001]
  • [Cites] Obstet Gynecol. 1999 Mar;93(3):363-6 [10074980.001]
  • [Cites] Breast Cancer Res Treat. 1999 Jul;56(2):133-43 [10573106.001]
  • [Cites] Br J Cancer. 1988 Jun;57(6):601-3 [3044432.001]
  • [Cites] Drugs. 1989 Apr;37(4):451-90 [2661195.001]
  • [Cites] J Steroid Biochem. 1990 Jun 22;36(3):203-6 [2142233.001]
  • [Cites] Arch Intern Med. 1991 Sep;151(9):1842-7 [1888251.001]
  • [Cites] Clin Obstet Gynecol. 1992 Mar;35(1):28-39 [1544246.001]
  • [Cites] Fertil Steril. 1992 Nov;58(5):959-63 [1426382.001]
  • [Cites] Am J Obstet Gynecol. 1993 Feb;168(2):620-30 [8438940.001]
  • [Cites] Obstet Gynecol. 1993 May;81(5 ( Pt 1)):660-4 [8469450.001]
  • [Cites] J Ultrasound Med. 1993 May;12(5):275-80 [8345555.001]
  • [Cites] J Natl Cancer Inst. 1993 Nov 17;85(22):1850-5 [8230266.001]
  • [Cites] Lancet. 1994 Feb 19;343(8895):448-52 [7905955.001]
  • [Cites] Lancet. 1994 May 28;343(8909):1318-21 [7910323.001]
  • (PMID = 11286468.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Estrogen Receptor Modulators; 094ZI81Y45 / Tamoxifen; 7NFE54O27T / Toremifene
  • [Other-IDs] NLM/ PMC2363827
  •  go-up   go-down


6. Hoogendoorn WE, Hollema H, van Boven HH, Bergman E, de Leeuw-Mantel G, Platteel I, Fles R, Nederlof PM, Mourits MJ, van Leeuwen FE, Comprehensive Cancer Centers TAMARISK-group: Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer. Breast Cancer Res Treat; 2008 Nov;112(1):99-108
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer.
  • We examined histopathologic and immunohistochemical characteristics of 332 patients with uterine corpus cancer following breast cancer, according to tamoxifen use.
  • An increased proportion of FIGO stage III and IV tumors was also observed (20.0% vs. 11.3%, P=0.049).
  • Within FIGO stage I, both short-term and long-term tamoxifen users showed a higher proportion of tumors limited to the endometrium than non-users (35.7% vs. 22.9%, P=0.049 and 0.004 respectively).
  • Our results can be applied when weighing risks and benefits of tamoxifen versus other hormonal agents used in the prevention and treatment of breast cancer.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Breast Neoplasms / drug therapy. Tamoxifen / therapeutic use. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma, Clear Cell / chemically induced. Adenocarcinoma, Clear Cell / diagnosis. Adenocarcinoma, Clear Cell / mortality. Aged. Cohort Studies. Cystadenocarcinoma, Serous / chemically induced. Cystadenocarcinoma, Serous / diagnosis. Cystadenocarcinoma, Serous / mortality. Endometrial Neoplasms / chemically induced. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / mortality. Female. Follow-Up Studies. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasm Staging. Neoplasms, Second Primary / chemically induced. Neoplasms, Second Primary / diagnosis. Prognosis. Retrospective Studies. Risk Factors. Sarcoma / chemically induced. Sarcoma / diagnosis. Sarcoma / mortality. Survival Rate


7. Kim JY, Lim SJ, Park K, Lee CM, Kim J: Cyclooxygenase-2 and c-erbB-2 expression in uterine cervical neoplasm assessed using tissue microarrays. Gynecol Oncol; 2005 May;97(2):337-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chemotherapeutic agents targeting COX-2 and c-erbB-2 are used to treat colon and breast cancers.
  • COX-2 protein expression was noted in 140 cases of uterine cervical neoplasm (44.0%): In 26.7% of the cervical intraepithelial neoplasia III (16/60 cases), 37.9% of the microinvasive squamous cell carcinoma (39/103 cases), 51.6% of the invasive squamous cell carcinoma (64/124 cases), and 76.2% of the adenocarcinomas (16/21 cases) (P < 0.005).
  • COX-2 protein expression correlated with histology (P < 0.005) and stage (P < 0.05), but was not associated with patient survival.
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Adenoid Cystic / enzymology. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Squamous Cell / enzymology. Carcinoma, Squamous Cell / pathology. Cyclooxygenase 2. Female. Humans. Immunohistochemistry. Membrane Proteins. Microarray Analysis. Middle Aged


8. Petit T, Borel C, Ghnassia JP, Rodier JF, Escande A, Mors R, Haegelé P: Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting. Clin Cancer Res; 2001 Jun;7(6):1577-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting.
  • All tumors were stage II or noninflammatory stage III adenocarcinoma.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Antibiotics, Antineoplastic / therapeutic use. Antibodies, Monoclonal / therapeutic use. Breast Neoplasms / drug therapy. Receptor, ErbB-2 / biosynthesis. Treatment Outcome
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adult. Aged. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents, Alkylating / therapeutic use. Cyclophosphamide / therapeutic use. Dose-Response Relationship, Drug. Epirubicin / therapeutic use. Female. Fluorouracil / therapeutic use. Humans. Immunohistochemistry. Middle Aged. Multivariate Analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11410493.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antibiotics, Antineoplastic; 0 / Antibodies, Monoclonal; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide; EC 2.7.10.1 / Receptor, ErbB-2; U3P01618RT / Fluorouracil
  •  go-up   go-down


9. Sève P, Dumontet C: Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol; 2008 Feb;9(2):168-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?
  • On the basis of preclinical studies that show overexpression of class III beta-tubulin is associated with resistance to tubulin-binding agents, several investigators have addressed the relation between class III beta-tubulin and outcome in patients treated with such agents.
  • High expression of class III beta-tubulin has been found to be correlated either with low response rates in patients treated with regimens containing taxanes or vinorelbine or with reduced survival in patients with non-small-cell lung cancer, in breast, ovarian, and gastric cancers, and in cancers of unknown primary site.
  • Two studies have shown patients with advanced non-small-cell lung cancer receiving paclitaxel whose tumours expressed high levels of class III beta-tubulin had a lower response to paclitaxel and shorter survival, whereas this variable was not found to be predictive in patients receiving regimens without tubulin-binding agents.
  • Conversely, analysis of samples from patients in the JBR-10 trial, which compared adjuvant chemotherapy to no further therapy in operable non-small-cell lung cancer, showed that chemotherapy seemed to overcome the negative prognostic effect of high levels of expression of class III beta-tubulin and the greatest benefit from cisplatin/vinorelbine was seen in patients with high levels of expression of class III beta-tubulin.
  • Further analyses in operable and advanced non-small-cell lung cancer showed a relation between high expression of class III beta-tubulin and baseline factors such as age under 60 years, adenocarcinoma and large-cell carcinoma histologies, and advanced stage of disease.
  • These results suggest that class III beta-tubulin could be both a prognostic and a predictive factor.
  • Large randomised studies are warranted to determine the prognostic or predictive value of class III beta-tubulin in different settings and tumours.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Drug Resistance, Neoplasm / physiology. Neoplasms / drug therapy. Tubulin / biosynthesis. Tubulin Modulators / pharmacology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18237851.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Tubulin; 0 / Tubulin Modulators
  • [Number-of-references] 60
  •  go-up   go-down


10. Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, Zambetti M, Vazquez F, Byakhow M, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Baronio R, Feyereislova A, Barton C, Valagussa P, Baselga J: Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet; 2010 Jan 30;375(9712):377-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
  • BACKGROUND: The monoclonal antibody trastuzumab has survival benefit when given with chemotherapy to patients with early, operable, and metastatic breast cancer that has HER2 (also known as ERBB2) overexpression or amplification.
  • We aimed to assess event-free survival in patients with HER2-positive locally advanced or inflammatory breast cancer receiving neoadjuvant chemotherapy with or without 1 year of trastuzumab.
  • METHODS: We compared 1 year of treatment with trastuzumab (given as neoadjuvant and adjuvant treatment; n=117) with no trastuzumab (118), in women with HER2-positive locally advanced or inflammatory breast cancer treated with a neoadjuvant chemotherapy regimen consisting of doxorubicin, paclitaxel, cyclophosphamide, methotrexate, and fluorouracil.
  • Randomisation was done with a computer program and minimisation technique, taking account of geographical area, disease stage, and hormone receptor status.
  • FINDINGS: Trastuzumab significantly improved event-free survival in patients with HER2-positive breast cancer (3-year event-free survival, 71% [95% CI 61-78; n=36 events] with trastuzumab, vs 56% [46-65; n=51 events] without; hazard ratio 0.59 [95% CI 0.38-0.90]; p=0.013).
  • Both responded to cardiac drugs.
  • INTERPRETATION: The addition of neoadjuvant and adjuvant trastuzumab to neoadjuvant chemotherapy should be considered for women with HER2-positive locally advanced or inflammatory breast cancer to improve event-free survival, survival, and clinical and pathological tumour responses.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Receptor, ErbB-2 / drug effects

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • [CommentIn] Lancet. 2010 Jan 30;375(9712):349-50 [20113810.001]
  • (PMID = 20113825.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN86043495
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab; P88XT4IS4D / Paclitaxel; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


11. Oliveira AL, Rodrigues FF, Santos RE, Aoki T, Rocha MN, Longui CA, Melo MB: GSTT1, GSTM1, and GSTP1 polymorphisms and chemotherapy response in locally advanced breast cancer. Genet Mol Res; 2010;9(2):1045-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GSTT1, GSTM1, and GSTP1 polymorphisms and chemotherapy response in locally advanced breast cancer.
  • The glutathione S-transferase (GST) family consists of phase II detoxification enzymes that catalyze the conjugation of toxic substances, such as chemotherapeutic agents, to glutathione.
  • We examined whether GSTT1/GSTT1"null", GSTM1/GSTM1"null" and GSTP1Ile105Ile/GSTP1Ile105Val polymorphisms are associated with different response rates to neoadjuvant chemotherapy in the treatment of stage II and III breast cancer.
  • Forty Brazilian women with invasive ductal adenocarcinoma of the breast submitted to neoadjuvant chemotherapy, using 5-fluorouracil, epirubicin and cyclophosphamide, were genotyped for the GSTT1, GSTM1 and GSTP1 genes.
  • Comparisons were made for the three genes alone and in pairs, as polymorphic and as wild-type combinations and polymorphic/wild-type combinations.
  • Analysis of all possible combinations showed the GSTM1"null" polymorphic genotype to be present in four, and the wild-type GSTP1105Ile in six of the combinations associated with the largest number of responding patients.
  • We found that patients with the GSTT1/GSTP1105Ile wild-type combination had a significantly higher response rate to chemotherapy than patients with the respective polymorphic GSTT1"null"/GSTP1105Val combination or patients with the wild-type GSTT1/GSTM1.
  • The six gene combinations associated with the largest number of responding patients were found to contain the wild-type GSTP1105Ile and the polymorphic-type GSTM1"null".
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / genetics. Glutathione S-Transferase pi / genetics. Glutathione Transferase / genetics. Polymorphism, Genetic
  • [MeSH-minor] Adult. Aged. Brazil. Carcinoma, Ductal, Breast / genetics. Cyclophosphamide / therapeutic use. Epirubicin / therapeutic use. Female. Fluorouracil / therapeutic use. Glutathione / metabolism. Humans. Middle Aged. Treatment Outcome


12. Cohen LF, Breslin TM, Kuerer HM, Ross MI, Hunt KK, Sahin AA: Identification and evaluation of axillary sentinel lymph nodes in patients with breast carcinoma treated with neoadjuvant chemotherapy. Am J Surg Pathol; 2000 Sep;24(9):1266-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification and evaluation of axillary sentinel lymph nodes in patients with breast carcinoma treated with neoadjuvant chemotherapy.
  • Sentinel lymph node (SLN) biopsy has been shown to predict axillary metastases accurately in early stage breast cancer.
  • Some patients with locally advanced breast cancer receive preoperative (neoadjuvant) chemotherapy, which may alter lymphatic drainage and lymph node structure.
  • Thirty-eight patients with stage II or III breast cancer treated with neoadjuvant chemotherapy were included.
  • Our findings indicate that lymph node mapping in patients with breast cancer treated with neoadjuvant chemotherapy can identify the SLN, and SLN biopsy in this group accurately predicts axillary nodal status in most patients.
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Carcinoma / drug therapy. Carcinoma / pathology. Lymph Nodes / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Axilla. Biopsy, Needle. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / surgery. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / pathology. Carcinoma, Lobular / surgery. Female. Humans. Immunohistochemistry. Keratins / analysis. Lymph Node Excision. Lymphatic Metastasis. Microtomy. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10976701.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 68238-35-7 / Keratins
  •  go-up   go-down


13. Shamseddine A, Khalifeh M, Chehal A, Saliba T, Mourad YA, Taher A, Jalloul R, Bitar N, Dandashi A, Abbas J, Geara FB: A clinical phase II study of cisplatinum and vinorelbine (PVn) in advanced breast carcinoma (ABC). Am J Clin Oncol; 2005 Aug;28(4):393-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A clinical phase II study of cisplatinum and vinorelbine (PVn) in advanced breast carcinoma (ABC).
  • OBJECTIVES: The effectiveness of cisplatinum and vinorelbine (PVn) as a salvage regimen in patients with metastatic breast cancer was reported in previous studies.
  • This report is a pilot study assessing the antitumor efficacy and safety of this regimen as first line therapy for advanced breast cancer patients.
  • METHODS: Thirty-five patients were enrolled: 22 with metastatic breast carcinoma and 13 with locally advanced breast carcinoma (stage III).
  • After the 4th cycle, patients with metastatic breast cancer received vinorelbine biweekly until disease progression or for a total of 12 cycles, whereas those with locally advanced breast cancer who showed complete or partial response underwent curative surgery.
  • For the metastatic breast cancer group, the overall response rate was 64%, with a median survival of 19 months (range 2-36).
  • For the locally advanced breast cancer group, the overall response rate was 92.3% with a median time to disease progression of 26 months (range 25-27).
  • CONCLUSIONS: PVn is effective as first line treatment of advanced breast cancer with overall response rate of 64% in metastatic breast cancer and 92.3% in locally advanced breast cancer, and acceptable toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / secondary. Adult. Aged. Bone Neoplasms / secondary. Carcinoma, Ductal / drug therapy. Carcinoma, Ductal / mortality. Carcinoma, Ductal / pathology. Carcinoma, Ductal / secondary. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / mortality. Carcinoma, Lobular / pathology. Carcinoma, Lobular / secondary. Cisplatin / administration & dosage. Female. Follow-Up Studies. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Pilot Projects. Skin Neoplasms / secondary. Survival Rate. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16062082.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


14. Yerushalmi R, Woods R, Kennecke H, Speers C, Knowling M, Gelmon K: Patterns of relapse in breast cancer: changes over time. Breast Cancer Res Treat; 2010 Apr;120(3):753-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of relapse in breast cancer: changes over time.
  • Adjuvant systemic treatment for breast cancer has evolved resulting in improved outcomes.
  • Women diagnosed with stage I-III breast cancer were divided into three time cohorts according to changes in adjuvant therapy; A: 1989-1991-CMF chemotherapy in premenopausal and tamoxifen for postmenopausal women; B: 1992-1997-anthracycline chemotherapy and tamoxifen for pre/postmenopausal women; C: 1998-2001-broader use of anthracyclines.
  • This may reflect the need for more successful adjuvant treatment options for aggressive breast cancer subtypes which are more likely to present with early spread to visceral organs.
  • [MeSH-major] Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / secondary. Breast Neoplasms / drug therapy. Chemotherapy, Adjuvant
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents, Hormonal / therapeutic use. British Columbia / epidemiology. Cohort Studies. Estrogens. Female. Humans. Incidence. Mastectomy / methods. Middle Aged. Neoplasms, Hormone-Dependent / drug therapy. Neoplasms, Hormone-Dependent / epidemiology. Neoplasms, Hormone-Dependent / radiotherapy. Neoplasms, Hormone-Dependent / surgery. Organ Specificity. Postmenopause. Premenopause. Radiotherapy, Adjuvant. Registries


15. Johnston SR: Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies. Clin Cancer Res; 2001 Dec;7(12 Suppl):4376s-4387s; discussion 4411s-4412s
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies.
  • Tamoxifen is one of the most effective treatments for breast cancer through its ability to antagonize estrogen-dependent growth by binding estrogen receptors (ERs) and inhibiting breast epithelial cell proliferation.
  • Several novel antiestrogen compounds have been developed that are also selective ER modulators (SERMs) but that have a reduced agonist profile on breast and gynecological tissues.
  • In advanced breast cancer clinical data exist for three first-generation SERMs (toremifene, droloxifene, idoxifene), which are related to the triphenylethylene structure of tamoxifen.
  • As first-line therapy for advanced breast cancer, the median response rate was 31% (range, 20-68%) with a median time to progression of 7 months.
  • Randomized Phase III trials for toremifene and idoxifene in more than 1500 patients showed no significant difference compared with tamoxifen.
  • The main advantage for SERM therapy probably remains in early stage-disease (adjuvant therapy or prevention), in which the estrogenic effects on bone and reduced gynecological side effects may prove more beneficial than either tamoxifen or AI.
  • The issue is whether the current clinical data for SERMs in advanced breast cancer are sufficiently strong to encourage that further development.
  • [MeSH-major] Adenocarcinoma / drug therapy. Breast Neoplasms / drug therapy. Neoplasms, Hormone-Dependent / drug therapy. Selective Estrogen Receptor Modulators / therapeutic use
  • [MeSH-minor] Clinical Trials as Topic. Estrogens / metabolism. Female. Forecasting. Humans. Receptors, Estrogen / drug effects

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11916228.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogens; 0 / Receptors, Estrogen; 0 / Selective Estrogen Receptor Modulators
  • [Number-of-references] 119
  •  go-up   go-down






Advertisement